Heptares Therapeutics Ltd, the drug discovery company focused on G-protein-coupled receptor (GPCR) targets, announces that it is relocating to the BioPark in Welwyn Garden City, between London and Cambridge, from its laboratories in Mill Hill, North London, where it has been based since founding in 2007. The new facility provides office and laboratory space and will enable Heptares to meet its future growth requirements following the successful raising of £21 million in a Series A fundraising completed in February 2009.

The Company currently has 15 employees and is aiming to more than double employee numbers over the next year. This expansion will allow it to consolidate its StaR™ GPCR biophysics and structural platform, and to build core chemistry and pharmacology capabilities in-house.

Heptares’ CEO, Dr Malcolm Weir, said: “Heptares has progressed rapidly since 2007, and the new funds we raised earlier this year have given us a very good opportunity to implement our strategy for generating new drug candidates to highly validated but previously challenging GPCRs. We are pleased to move to the Welwyn BioPark, which provides a first-class research environment within easy reach of London and Cambridge, where we retain excellent scientific links.”

The Company’s new address as from 12 May 2008 is:

Heptares Therapeutics Ltd
BioPark
Broadwater Road
Welwyn Garden City
Hertfordshire
AL7 3AX

Tel: +44 (0)1707 356 100

www.heptares.com